Data / Form D filings / PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc.: Form D filings
PharmaCyte Biotech, Inc., a biotechnology company in Las Vegas, NV, filed 4 Form D notices with the SEC between 2013 and 2025. The latest, on September 4, 2025, reports $7 million sold of a $7 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3960 HOWARD HUGHES PARKWAY, SUITE 500, Las Vegas, NV, 89169
- Phone
- (917) 595-2850
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Nevada
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1157075
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2025 | New notice | $7,000,000 | $7,000,000 | 12 | Aug 17, 2025 | sec.gov | |
| Sep 1, 2021 | New notice | $70,000,000 | $70,000,000 | 19 | Aug 23, 2021 | sec.gov | |
| Jan 19, 2016 | New notice | $3,060,000 | $1,020,000 | $2,040,000 | 2 | Jan 7, 2016 | sec.gov |
| Dec 27, 2013 | New notice | $3,500,000 | $1,136,000 | $2,364,000 | 21 | Apr 27, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robert M. Weinstein | Director | |
| Jonathan L. Schechter | Director | |
| Michael M. Abecassis | Director | |
| Carlos N. Trujillo | Executive Officer | |
| Joshua N. Silverman | Executive Officer, Director | |
| Walker R. Wayne | Director |
Other biotechnology companies in Nevada that filed recently
- Palimpsest Bio Corp. $172,000 · Oct 30, 2026
- Conexeu Sciences Inc. $1.5 million · Oct 21, 2026
Every Form D from the week of Sep 1, 2025 · All recent filings in Nevada · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what PharmaCyte Biotech, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.